Ritter Pharmaceuticals (NASDAQ: RTTR) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Ritter Pharmaceuticals to related businesses based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.
Risk and Volatility
Ritter Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals’ peers have a beta of 5.91, meaning that their average share price is 491% more volatile than the S&P 500.
This is a summary of current ratings for Ritter Pharmaceuticals and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ritter Pharmaceuticals Competitors||1133||3423||11925||240||2.67|
Ritter Pharmaceuticals currently has a consensus price target of $2.50, suggesting a potential upside of 608.22%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.62%. Given Ritter Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Ritter Pharmaceuticals is more favorable than its peers.
Institutional & Insider Ownership
33.4% of Ritter Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 28.1% of Ritter Pharmaceuticals shares are held by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Ritter Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ritter Pharmaceuticals||N/A||-$18.38 million||-0.30|
|Ritter Pharmaceuticals Competitors||$290.27 million||$35.99 million||59.18|
Ritter Pharmaceuticals’ peers have higher revenue and earnings than Ritter Pharmaceuticals. Ritter Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Ritter Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ritter Pharmaceuticals Competitors||-5,441.68%||-162.70%||-35.92%|
Ritter Pharmaceuticals peers beat Ritter Pharmaceuticals on 7 of the 12 factors compared.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.